ライフサイエンスコーパス: factor Xa inhibitor

1 ithin 18 hours after the administration of a factor Xa inhibitor.

2 Otamixaban is an intravenous direct factor Xa inhibitor.

3 y potent, selective, and orally bioavailable factor Xa inhibitor.

4 gned to reverse the anticoagulant effects of factor Xa inhibitors.

5 atheter ablation in AF patients treated with factor Xa inhibitors.

6 available in the United States for the oral factor Xa inhibitors.

7 n amide that is found in previously reported factor Xa inhibitors.

8 nt a novel class of potent dual thrombin and factor Xa inhibitors.

9 y potent, selective, and orally bioavailable factor Xa inhibitors.

10 For each factor Xa inhibitor, a two-part randomized placebo-contr

11 on with anticoagulants (thrombin inhibitors, factor Xa inhibitors) act synergistically in inhibiting

12 Apixaban, an oral factor Xa inhibitor administered in fixed doses, may sim

13 Factor Xa inhibitors and aspirin each reduce thrombotic

14 A number of oral direct factor Xa inhibitors and oral direct thrombin inhibitors

15 erruption, or discontinuation of direct oral factor Xa inhibitor) and the remaining eight (14%) event

16 se of anticoagulants (vitamin K antagonists, factor Xa inhibitors, and direct thrombin inhibitors) fo

17 Compared with warfarin, factor Xa inhibitors are associated with a lower risk of

18 ry and SAR of ketopiperazino methylazaindole factor Xa inhibitors are described.

19 Two direct factor Xa inhibitors are emerging from phase II trials (

20 Oral direct factor Xa inhibitors are potentially well tolerated and

21 s), including direct thrombin inhibitors and factor Xa inhibitors, are emerging options for thrombopr

22 Is treatment with factor Xa inhibitors associated with better efficacy and

23 xtended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of str

24 he carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond

25 Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents f

26 Compared with LMWH, lower doses of oral factor Xa inhibitors can achieve a small absolute risk r

27 Factor Xa inhibitors can prevent 4 instances of symptoma

28 onfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events

29 ractions that were not found in the previous factor Xa/inhibitor complexes.

30 The factor Xa inhibitor DEGR-chloromethyl ketone and an anti

31 ived data from phase 3 trials of direct oral factor Xa inhibitors done at University Hospital Carl Gu

32 Whether the oral factor Xa inhibitor edoxaban can be an alternative to wa

33 The oral factor Xa inhibitor edoxaban has demonstrated safety and

34 rombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin

35 on, was completely inactive as a thrombin or factor Xa inhibitor even after heparin activation.

36 Treatment of mice with the factor Xa inhibitor fondaparinux during the last 4 wk of

37 eral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analog) and a direct t

38 considerable interest in the development of factor Xa inhibitors for the intervention in thrombic di

39 been intense interest in the development of factor Xa inhibitors for the treatment of thrombotic dis

40 Compound 1 was the first non-amidine factor Xa inhibitor from our lab that had measurable pot

41 A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective a

42 agulants (nOAC), which includes thrombin and factor Xa inhibitors, has been shown to be effective, bu

43 nhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and eff

44 The use of an oral factor Xa inhibitor in patients stabilised after an acut

45 ctive, reversible, and direct small-molecule factor Xa inhibitor in patients with stable coronary dis

46 omplications during therapy with direct oral factor Xa inhibitors in a case series of women of reprod

47 ivaroxaban, apixaban, and edoxaban, the oral factor Xa inhibitors in the most advanced stages of deve

48 the foundation for further investigation of factor Xa inhibitors in the treatment of patients with c

49 High, but not lower, doses of oral factor Xa inhibitors increased bleeding compared with LM

50 Highly convergent synthesis of these factor Xa inhibitors is also described.

51 Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may r

52 Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of s

53 The direct factor Xa inhibitors may offer several promising alterna

54 Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and pre

55 Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent is

56 oral anticoagulants, such as factor IIa and factor Xa inhibitors, may provide a novel treatment appr

57 in clinical trials suggest that direct oral factor Xa inhibitors might increase menstrual bleeding i

58 Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared w

59 Therefore, development of the oral factor Xa inhibitors represents a translational science

60 SAR107375), a novel potent dual thrombin and factor Xa inhibitor resulted from a rational optimizatio

61 The factor Xa inhibitor rivaroxaban reduced mortality and is

62 The oral factor Xa inhibitor rivaroxaban was noninferior to warfa

63 thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new or

64 Recently, the oral factor Xa inhibitors rivaroxaban and apixaban have enter

65 he effects of the DTI dabigatran, the direct factor Xa-inhibitor rivaroxaban, and of 2-O, 3-O desulfa

66 twice daily [BID], 110 mg BID), and the oral Factor Xa inhibitors, rivaroxaban and apixaban.

67 inhibitor, dabigatran etexilate, and the two factor Xa inhibitors, rivaroxaban and apixaban.

68 The specific factor Xa inhibitor rTAP, when given in fully anticoagul

69 s incorporated into a previously established factor Xa inhibitor series.

70 Apixaban, an oral factor Xa inhibitor that can be administered in a simple

71 Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in preventio

72 Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the ri

73 Rivaroxaban is a factor Xa inhibitor that was recently reviewed by the Fo

74 loped a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl

75 n a series of potent and orally bioavailable factor Xa inhibitors that ultimately led to the discover

76 of reproductive age treated with direct oral factor Xa inhibitors: the non-interventional Dresden NOA

77 of reproductive age who received direct oral factor Xa inhibitor therapy, of whom 57 had vaginal blee

78 in women of reproductive age on direct oral factor Xa inhibitor therapy.

79 pathway inhibitor (TFPI), and the selective factor Xa inhibitor, tick anticoagulant peptide (TAP), a

80 d conformations of (13)C,(15)N,(19)F-labeled factor Xa inhibitors to bovine trypsin.

81 Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazol

82 f an ongoing effort to prepare orally active factor Xa inhibitors using structure-based drug design t

83 In the secondary analysis, factor Xa inhibitors were associated with a reduced risk

84 Factor Xa inhibitors were associated with a reduction in

85 Factor Xa inhibitors were associated with lower rates of

86 luded because of the intake of a direct oral factor Xa inhibitor which has a strong impact on prothro

87 highly potent, selective, and orally active factor Xa inhibitor which was chosen for clinical develo

88 Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninf

89 Studies of antistasin, a potent factor Xa inhibitor with anticoagulant properties, were

90 ther optimize the selectivity profile of our factor Xa inhibitors with a series of ortho- and/or para

91 combined treatment of aspirin or C921-78 (a factor Xa inhibitor) with CT50547 or 2-MeSAMP (a P2Y12 a

92 ts with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurrin

93 mbinant tick anticoagulant peptide (rTAP), a factor Xa inhibitor, would reduce the thickness of neoin